Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Future Innovative Treatments

Neither a doctor nor a teaching hospital

Research payments

$3,985,554

70 payments

Through program year 2022, Future Innovative Treatments is reported as receiving $3,985,554 in research payments, across 70 payments.

By program year

3 rows
Year Kind Amount Payments
2022 Research $381,373 1
2021 Research $3,589,886 64
2019 Research $14,295 5

Breakdown

Who paid Research payments · program years 2019–2022
  1. Regeneron Pharmaceuticals, Inc. $3,127,568 61 payments
  2. Novartis Pharmaceuticals Corporation $808,791 3 payments
  3. AstraZeneca Pharmaceuticals LP $34,900 1 payment
  4. Ironwood Pharmaceuticals, Inc $14,295 5 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $1,809,099 34 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $1,154,862 22 payments
  3. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 (The Empathy Trial) $427,418 2 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ensovibep (Mp0420) in Ambulatory Adult Patients With Symptomatic Covid-19 $381,373 1 payment
  5. A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $163,607 5 payments
  6. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacodynamic Effects of MEDI0382 in Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) $34,900 1 payment
  7. McP-103-205 $14,295 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record